[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Affiliated Hospital of Qingdao University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":617},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,29,0,25,[9,49,76,102,127,153,180,208,233,255,277,302,330,353,381,399,422,452,472,490,505,526,547,569,591],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100644891","phase-1-a-study-of-c-car168-in-the-treatment-of-autoimmune-diseases-refractory-to-standard-therapy-100644891",false,"NCT07676266","A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy","An Exploratory Clinical Study of Anti-CD20\u002FB-cell Maturation Antigen (BCMA) Chimeric Antigen Receptor Autologous T Cell Product (C-CAR168) in the Treatment of Autoimmune Diseases Refractory to Standard Therapy","Inclusion Criteria:\n\n* 18 to 70 years old at the time of signing the Informed Consent Form (ICF).\n* Diagnosed as Multiple sclerosis (MS)\u002FNeuromyelitis Optica Spectrum Disorders (NMOSD)\u002FMyasthenia Gravis (MG)\u002FSystemic Lupus Erythematosus (SLE)\u002F Systemic Sclerosis (SSc)\u002F Immune-Mediated Necrotizing Myopathy (IMNM) according to recognized diagnostic criteria for at least 6 months.\n* Prior treatment failure with standard therapy.\n* Adequate bone marrow, coagulation, cardiopulmonary, liver and renal function.\n\nExclusion Criteria:\n\n* Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Treponema Pallidum (TP) positive, Cytomegalovirus (CMV) DNA positive, Epstein-Barr Virus (EBV) DNA positive.\n* Uncontrolled active infection.\n* Live vaccine injection within 4 weeks prior to signing the ICF.\n* Major organ transplantation history or bone marrow\u002Fhematopoietic stem cell transplantation history.\n* Severe cardiovascular diseases within the past 6 months prior to screening.\n* A history of ≥ Grade 2 bleeding within 4 weeks prior to screening, or requiring long-term anticoagulants treatment.\n* Inadequate washing time for previous treatment.\n* Previously treated with CAR-T cell products or genetically modified T cell therapies.\n* Pregnant or lactating women.\n* Severe central nervous system diseases or pathological changes.\n* Malignancy history within 5 years prior to signing the ICF.\n* Any contraindication to lumbar puncture for MS or NMOSD.","ALL","18 Years","70 Years",{"count":21,"type":22},18,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy",[28,29,30,31,32,33],"Multiple Sclerosis (MS)","Myasthenia Gravis (MG)","Neuromyelitis Optica Spectrum Disorder","Systemic Lupus Erythematosus","Systemic Sclerosis","Immune-Mediated Necrotizing Myopathy",[35],"CD20\u002FBCMA-directed CAR-T cells","NOT_YET_RECRUITING","2026-06-24",{"date":39,"type":40},"2026-06-30","ACTUAL",{"date":42,"type":22},"2026-07",{"date":44,"type":22},"2028-10",{"name":46,"class":47},"The Affiliated Hospital of Qingdao University","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100605809","phase-4-the-effect-of-oral-clostridium-butyricum-on-the-recurrence-after-colonoscopic-resection-of-colorectal-adenoma-100605809","NCT07167342","The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma","The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma - A Multicenter, Double-blinded, Differential Design, Randomized, Placebo-controlled Study","Inclusion Criteria:\n\n* Age between 18 and 75 years\n* No restriction on sex\n* Boston Bowel Preparation Score (BBPS) ≥ 7 prior to endoscopic procedure\n* Completed endoscopic resection of colorectal adenomas (including cold snare polypectomy, ESD, EMR, etc.) with no residual adenomas or polyps observed endoscopically\n* Histologically confirmed adenomas (including tubular, villous, or tubulovillous types) without malignant transformation\n* Able to take oral medication\n* Signed informed consent\n\nExclusion Criteria:\n\n* Use of probiotics, prebiotics, synbiotics, or antibiotics within 2 weeks prior to enrollment\n* Presence of psychiatric disorders or other conditions preventing compliance with the intervention\n* Dysfunction of vital organs (liver, kidney, heart, etc.) deemed unsuitable for clinical study participation after evaluation\n* Participation in other clinical trials within 3 months prior to enrollment\n* History of gastrointestinal surgery (excluding endoscopic procedures)\n* History of inflammatory bowel disease\n* History of autoimmune diseases\n* Long-term use of aspirin (≥100 mg\u002Fday for over 3 months) or calcium supplements (≥1200 mg\u002Fday for over 3 months)\n* Pregnancy or breastfeeding\n* Previous treatment for colorectal adenomas (including endoscopic or surgical resection)\n* Familial adenomatous polyposis (FAP)","75 Years",{"count":58,"type":22},294,[60],"PHASE4","The prevention of recurrence after colorectal adenoma resection remains an urgent medical issue to be addressed. Previous studies have mainly focused on nonsteroidal anti-inflammatory drugs, calcium supplements, and vitamins. The gut microbiota and its metabolic products are believed to play a potential role in the development and progression of colorectal adenomas. Clostridium butyricum, a butyrate-producing probiotic, has not yet been studied for its potential in preventing the recurrence of colorectal adenomas following resection. Therefore, this study, designed as a multicenter, double-blind, placebo-controlled randomized controlled trial, aims to explore evidence-based data on the role of Clostridium butyricum in preventing colorectal adenoma recurrence.",[63,64],"Colorectal Adenoma","Probiotics",[63,66],"Clostridium butyricum","RECRUITING","2026-05-22",{"date":70,"type":40},"2026-05-26",{"date":68,"type":40},{"date":73,"type":22},"2030-04-30",{"name":46,"class":47},2,{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100628762","bed-rest-duration-and-outcomes-in-endoscopic-skull-base-reconstruction-100628762","NCT07465861","Bed Rest Duration and Outcomes in Endoscopic Skull Base Reconstruction","The Impact of Postoperative Bed Rest Duration on the Reconstruction Outcomes of Endoscopic Endonasal Midline Anterior Skull Base Surgery: A Multicenter Randomized Controlled Trial","BRO","Inclusion Criteria:\n\n1. Male and female patients aged 18-75 years.\n2. Scheduled to undergo endoscopic endonasal midline anterior skull-base surgery with an anticipated risk of intraoperative cerebrospinal fluid leak.\n3. Pre-operatively alert, with normal limb mobility, able to comply with both post-operative bed-rest and non-bed-rest protocols.\n4. Absence of severe cardiopulmonary dysfunction or any other comorbidity that would compromise tolerance of general anesthesia or surgical intervention.\n5. Good patient compliance, voluntary participation in this clinical study, and signed informed consent.\n\nExclusion Criteria:\n\n1. Pre-existing bed-rest-related complications such as hypostatic pneumonia, lower-extremity venous thrombosis, or pressure ulcers.\n2. Anticipated requirement for prolonged post-operative bed rest.\n3. No cerebrospinal fluid leakage occurred during surgery, or dural defect extending beyond the midline anterior skull-base region.\n4. Any other condition that, in the investigator's opinion, renders the participant unsuitable for enrollment.\n5. Patients with poor treatment compliance.",{"count":85,"type":22},316,[87],"NA","This study is a randomized controlled trial conducted across multiple centers. Due to the anatomical and pathological complexity of endoscopic endonasal skull base surgery, the study scope was restricted to the midline anterior skull base region to maximize homogeneity among enrolled cases.\n\nAfter screening according to inclusion and exclusion criteria and obtaining informed consent, patients were intraoperatively classified into low-flow cerebrospinal fluid (CSF) leak (dural defect ≤1 cm²) or high-flow CSF leak (dural defect \\>1 cm²) groups. Patients in the low-flow group were randomly assigned to either a non-bed-rest group or a 2-day bed-rest group, while those in the high-flow group were randomly assigned to either a 1-day or a 3-day bed-rest group.\n\nThe primary outcome was the reconstruction success rate (from immediately postoperative to 1 month) compared between different bed-rest durations within the low-flow and high-flow subgroups, respectively. Secondary outcomes included the incidence of bed-rest-related postoperative adverse events during hospitalization (safety indicator), postoperative quality-of-life scores (functional indicator), length of postoperative hospital stay (days), and total treatment cost (healthcare resource utilization indicator).\n\nBy comparing these outcomes across groups, the study aims to evaluate the impact of bed-rest duration on the outcomes of endoscopic endonasal reconstruction of the midline anterior skull base, thereby providing high-quality clinical evidence to facilitate accelerated postoperative recovery.",[90],"Skull Base",[92,93,94],"Bed rest","Endoscopic surgery","Cerebrospinal fluid rhinorrhea","2026-04-01",{"date":97,"type":40},"2026-04-07",{"date":95,"type":22},{"date":100,"type":22},"2030-12-31",{"name":46,"class":47},{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},"100624059","phase-1-study-on-the-safety-and-efficacy-of-intratympanic-injection-of-small-extracellular-vesicles-derived-from-mesenchymal-stem-cells-in-severe-and-profound-sudden-sensorineural-hearing-loss-100624059","NCT07404709","Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss","Clinical Phase I and IIa Trials of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss","Inclusion Criteria:\n\n1. Sudden unilateral hearing loss that occurs within 72 hours, with a decrease of at least 30 decibels in at least 3 frequency ranges compared to the healthy ear, and an average pure tone threshold of ≥ 65 decibels.\n2. Enrollment must be completed within 7 days after the onset of sudden deafness.\n3. Men or women aged 18 to 65\n4. Not treated in any other hospital and not taking any treatment medication on one's own\n5. Be able to understand the trial protocol and undergo regular follow-up visits and check-ups\n\nExclusion Criteria:\n\n1. Pregnant or lactating women\n2. With a history of chronic ear diseases, ear surgery, autoimmune hearing loss or a confirmed diagnosis of Meniere's syndrome in the past\n3. Having received steroid treatment for any reason within the past 30 days\n4. There are autoimmune diseases or chronic inflammatory diseases.\n5. Severe damage to liver and kidney functions\n6. Patients with a previous history of cerebral hemorrhage or those currently taking anticoagulant medications\n7. Other cases in which the researchers judged the candidates to be unsuitable for inclusion","65 Years",{"count":111,"type":22},9,[25,113],"PHASE2","The goal of this clinical trial is to learn if small extracellular vesicles derived from mesenchymal stem cells work to treat severe and above sudden sensorineural hearing loss. It will also learn about the safety of small extracellular vesicles. The main questions it aims to answer are:\n\n1. Does small extracellular vesicles combined with traditional drug treatment improve hearing even better in severe and above sudden deafness participants?\n2. What medical problems do participants have with intratympanic injection of small extracellular vesicles? Researchers will compare small extracellular vesicles to dexamethasone to see if small extracellular vesicles work to treat severe and above sudden sensorineural hearing loss.\n\nIn clinical Phase I trial, the investigators will complete the safety check and dose exploration.\n\nParticipants will:\n\n1. Receive traditional drug treatment in accordance with the \"Guidelines for the Diagnosis and Treatment of Sudden Deafness (2015)\n2. Receive small extracellular vesicles or a placebo tympanic injection additionally\n3. Visit the clinic once every 2 weeks for checkups and tests\n4. Receive tympanic injections of small extracellular vesicles ranging from low concentration to high concentration\n5. Be evaluated for any adverse reactions In clinical Phase II trial, participants were randomly divided into a control group and an experimental group.\n\n   Participants will:\n6. Received intratympanic injections of small extracellular vesicles 3 times together with traditional drug treatment in experimental group\n7. Received intratympanic injections of 5mg dexamethasone 3 times together with traditional drug treatment in control group, also for a total of 3 times Visit the clinic once 7 days , 1month and 3 months after treatment for checkups and tests of pure tone audiometry, speech audiometry, tinnitus disability scale and visual analogue scale assessment",[116,117],"Sudden Hearing Loss","Extracellular Vesicles","2026-03-21",{"date":120,"type":40},"2026-03-25",{"date":122,"type":22},"2026-02-28",{"date":124,"type":22},"2028-12-31",{"name":46,"class":47},5,{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":152},"100630303","phase-4-a-prospective-multicenter-exploratory-clinical-study-on-consolidation-therapy-with-tislelizumab-combined-with-nintedanib-for-limited-stage-small-cell-lung-cancer-100630303","NCT07485920","A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Have a thorough understanding of this study and have voluntarily signed the informed consent form;\n2. Age ≥ 18 years old, gender not restricted;\n3. ECOG score 0-1;\n4. Histologically or cytologically confirmed as limited-stage small cell lung cancer;\n5. At least one measurable lesion (according to RECISTv1.1 criteria);\n6. Expected survival ≥ 3 months;\n7. Prophylactic cranial radiotherapy is permitted before consolidation therapy;\n8. Adequate organ function reserve. The subjects must meet the following laboratory indicators: Before the sample collection during the screening period, the patient has not received blood transfusion or growth factor support treatment for ≤ 14 days and: absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL, platelets ≥ 100 × 109\u002FL, hemoglobin ≥ 90 g\u002FL，Calculated creatinine clearance rate (CrCl) (Cockcroft-Gault formula): creatinine clearance rate ≥ 60 mL\u002Fmin，Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN) (total bilirubin of Gilbert's syndrome patients must be \\\u003C 3 × ULN)，AST and ALT ≤ 2.5 × ULN，Patients not receiving anticoagulation treatment: international normalized ratio or activated partial thromboplastin time ≤ 1.5 × ULN，Albumin ≥ 25 g\u002FL (2.5 g\u002FdL).\n9. Willing and able to comply with the study plan's visits, treatment plan, laboratory tests and other research procedures;\n10. Pregnant women must undergo a serum pregnancy test 3 days before the first medication administration and the result must be negative. For pregnant women subjects and male subjects whose partners are pregnant women, they must agree to use effective contraceptive methods during the study and within 120 days after the last administration of the study drug.\n\nExclusion Criteria:\n\n1. There are patients with lung metastasis from other primary malignant tumors.\n2. Patients who have previously or concurrently had other systemic malignant tumors (excluding skin basal cell carcinoma, skin squamous cell carcinoma, and\u002For in situ cancer that has undergone radical resection), excluding those with cured skin basal cell carcinoma, skin squamous cell carcinoma, and\u002For in situ cancer that has undergone radical resection.\n3. Patients who have previously received other systemic treatments for the current lung cancer, including chemotherapy, immunotherapy, targeted therapy, or anti-angiogenic therapy, other than induction radiotherapy and chemotherapy.\n4. Patients who received other approved systemic immunomodulators (including but not limited to interferon, interleukin-2, tumor necrosis factor, thymus pentapeptide, and thymalfasin) within 4 weeks prior to the first administration.\n5. Patients whose blood pressure control is not satisfactory after drug treatment (systolic blood pressure ≥ 160 mmHg, diastolic blood pressure ≥ 100 mmHg).\n6. Patients with factors that significantly affect the absorption of oral medications, such as inability to swallow, chronic diarrhea, and intestinal obstruction, etc.\n7. The investigator judges that the possibility of tumor invasion of important blood vessels and fatal bleeding caused by the tumor is relatively high during the treatment process.\n8. Within 3 months before the study, there was significant clinical hemoptysis (more than 50 ml of hemoptysis per day), or there were significant clinical bleeding symptoms or obvious bleeding tendencies (such as gastrointestinal bleeding, gastric ulcer bleeding, gastrointestinal bleeding, hemorrhagic gastric ulcer, fecal occult blood ++ and above baseline, or having vasculitis, etc.)\n9. Within 14 days before the first administration of the study drug, any traditional Chinese medicine used for controlling cancer was used.\n10. Within 30 days before the first administration, the patient received live vaccines. Including but not limited to the following: mumps, rubella, measles, chickenpox\u002Fzoster (chickenpox), yellow fever, rabies, BCG (bacillus Calmette-Guérin), and typhoid vaccine (inactivated virus vaccine is allowed); or it is expected that the patient will need to receive live vaccines or attenuated live vaccines during the study period or within 5 months after the last administration\n11. Within 14 days before the first administration of the study drug, any situation where systemic treatment with corticosteroids (prednisone or equivalent drugs \\> 10 mg\u002Fday) or other immunosuppressive drugs is required, and the investigator assesses that it has an impact on the study treatment\n12. Patients with systemic autoimmune diseases that require systemic treatment, and the investigator assesses that it has an impact on the study treatment\n13. Patients with interstitial lung disease, non-infectious pneumonia, or other uncontrolled diseases, including diabetes, pulmonary fibrosis, acute lung disease, etc., and the investigator assesses that it has an impact on the study treatment\n14. Patients with a significant history of major diseases or clinical manifestations that may affect the function of organ systems, and the investigator assesses that it has an impact on the study treatment.\n15. Within 14 days before the first administration of the study drug, severe chronic or active infections (including tuberculosis infection, etc.) that require systemic antibacterial, antifungal, or antiviral treatment (including HBsAg positive in the screening period and HBV-DNA detection value higher than the upper limit of the laboratory test department of the research center; (for subjects who tested HBV-DNA content \\\u003C 500 IU\u002FmL within 28 days before enrollment and have received at least 14 days of local standard antiviral treatment and are willing to continue antiviral treatment during the study period, they can be enrolled); active hepatitis C (defined as HBsAb positive in the screening period and HCV-RNA positive) subjects.\n16. Uncontrolled active hepatitis B (defined as HBsAg positive in the screening period and HBV-DNA detection value higher than the upper limit of the laboratory test department of the research center; (for subjects who tested HBV-DNA content \\\u003C 500 IU\u002FmL within 28 days before enrollment and have received at least 14 days of local standard antiviral treatment and are willing to continue antiviral treatment during the study period, they can be enrolled); active hepatitis C (defined as HBsAb positive in the screening period and HCV-RNA positive) subjects\n17. Known human immunodeficiency virus (HIV) infection (known HIV antibody positive)\n18. Grade III-IV congestive heart failure (New York Heart Association classification), poorly controlled and with clinically significant arrhythmias\n19. Any occurrence of arterial thrombosis, embolism or ischemia within 6 months prior to the inclusion in the treatment, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, etc.\n20. Concurrent participation in another therapeutic clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.\n21. Medical history or disease evidence, abnormal treatment or laboratory test values that may interfere with the test results and prevent the subject from fully participating in the study, or other conditions that the investigator considers as other potential risks and unsuitable for inclusion in the study. The investigator considers that there are other potential risks that make participation in this study unsuitable.",{"count":134,"type":22},20,[60],"This study is a prospective, single-arm, multicenter, exploratory clinical trial. It aims to evaluate the efficacy and safety of tislelizumab combined with nintedanib as consolidation therapy for patients with limited-stage small cell lung cancer after concurrent chemoradiotherapy, and to explore the prognostic markers related to the therapeutic effect.",[138],"Limited-stage Small Cell Lung Cancer (LS-SCLC)",[140,141,142,143],"Limited-stage small cell lung cancer","consolidation therapy","tislelizumab","nintedanib","2026-03-17",{"date":146,"type":40},"2026-03-20",{"date":148,"type":22},"2026-05-01",{"date":150,"type":22},"2030-01-31",{"name":46,"class":47},6,{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":160,"targetDuration":4,"studyType":23,"phases":162,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":48},"100565861","phase-2-neoadjuvant-chemotherapy-and-pd-1-inhibitor-for-locally-advanced-rectal-cancercontrol-01-100565861","NCT06647680","Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）","Neoadjuvant Chemotherapy and Tislelizumab (PD-1 Inhibitior) for Locally Advanced Rectal Cancer: a Single-center, Prospective, Phase II Study","Inclusion Criteria:\n\n* Be willing and able to provide written informed consent for the trial\n* Age 18 years or greater\n* Pathologically proven diagnosis of adenocarcinoma of the rectum\n* Clinically determined to be stage T3 or T4, N0-N2, and M0\n* Be fully active, able to carry on all pre-disease performance without restriction or Restricted in physically strenuous activity.\n* Contrast-enhanced imaging of the abdomen and chest by CT to exclude distant metastases and provide local tumor stage\n* Preoperative ECOG status score 0-1\n* Preoperative ASA grade I-III\n* Adequate bone marrow function\n* Adequate renal and liver function\n* No active second cancers\n* Be willing and able to comply with all aspects of the protocol\n* Women of childbearing potential must have used reliable contraception or have had a pregnancy test result within 7 days prior to enrollment. Be negative and willing to use an adequate method of contraception for the duration of the trial and for 8 weeks after the last administration of the trial drug.\n* Adequate bone marrow function defined as follows: Absolute neutrophil count (ANC) ≥ 1,200 cells\u002Fmm3 Platelets ≥ 100,000 cells\u002Fmm3 Hemoglobin ≥ 8.0 g\u002Fdl.\n* Adequate hepatic function within within 28 days before registration on this study:total bilirubin must be ≤ ULN (upper limit of normal) for the lab unless the patient has a bilirubin elevation \\> ULN to 1.5 x ULN due to Gilbert\\'s disease or similar syndrome involving slow conjugation of bilirubin; and AST and ALT must be ≤3 x ULN for the lab If AST and\u002For ALT is ≥ ULN but ≤ 3 x ULN, serologic testing for Hepatitis B and C must be performed and results for viral infection must be negative.\n* Adequate renal function within 28 days before randomization defined as serum creatinine ≤ 1.5 x ULN for the lab or calculated creatinine clearance \\> 30 mL\u002Fmin\n\nExclusion Criteria:\n\n* Age less than 18 years\n* Pregnant or breastfeeding women\n* Prior invasive malignancy unless disease free for a minimum of three years\n* Preoperative body temperature ≥ 38°C or concurrent infectious diseases requiring systemic therapy;\n* Severe mental illness;\n* Severe abnormal heart, lung and kidney function\n* History of unstable angina pectoris or myocardial infarction within 6 months;\n* History of cerebral infarction or cerebral hemorrhage within 6 months;\n* Patients with abnormal coagulation function;\n* Have a history of psychotropic drug abuse or have a mental disorder;\n* Continuous use of glucocorticoids within 1 month (except topical application);\n* Patient has participated in or is participating in other clinical studies (within 6 months);\n* According to the judgment of the investigator, it endangers the patient\\'s health or affects the experimental results.",{"count":161,"type":22},35,[113],"To evaluate the safety and preliminary efficacy of preoperative chemotherapy and PD-1 inhibitor Tislelizumab for Rectal Cancer patients.Go through laboratory and medical tests to verify eligibility to enter the study, receive the experimental combination of drugs CAPOX (Oxaliplatin and Capecitabine) for 3 cycles prior to surgery and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three years.",[165],"Rectal Cancer Patients",[167,168,169,170,171],"Rectal cancer","Chemotherapy","Tislelizumab","Complete response","Recurrence free survival","2026-03-05",{"date":174,"type":40},"2026-03-06",{"date":176,"type":40},"2025-06-01",{"date":178,"type":22},"2027-12-01",{"name":46,"class":47},{"id":181,"slug":182,"hasResults":12,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":23,"phases":190,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":48},"100506185","phase-3-laparoscopic-gastrectomy-with-d2-lymphadenectomy-combined-with-hyperthermic-intraperitoneal-chemotherapy-hipec-or-not-100506185","NCT05871099","Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not","Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer After Laparoscopic Gastrectomy With D2 Lymphadenectomy: A Phase III Multicenter Prospective Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n(1) Newly treated patients who did not receive chemotherapy, radiotherapy or other antitumor therapy before the start of the clinical trial;(2) Aged 18-80 years;(3) male or non-pregnant or lactating female;(4) Gastric adenocarcinoma was pathologically confirmed, and laparoscopic (robotic) radical gastrectomy was planned;(5) Patients with T stage T3 or above, no distant metastasis, and feasible criteria for laparoscopic D2 radical resection (AJCC Eighth edition);(6) The estimated survival time is more than 6 months;(7) History of nonabdominal surgery (except laparoscopic cholecystectomy);(8) The bone marrow reserve function was good, and the blood routine met the following conditions: white blood cell count ≥3.5×109\u002FL, neutrophil ≥1.5×109\u002FL, platelet count ≥100×109\u002FL, hemoglobin ≥90g\u002FL;(9) Organ function was good, and biochemical examination met the following conditions: ALT≤2.5× upper limit of normal value (ULN), AST≤2.5×ULN, serum total bilirubin ≤1.5×ULN, serum creatinine ≤1.5×ULN;(10) Functional status: 0-1 (ECOG);(11) Preoperative ASA grade I-III;(12) Voluntarily sign the informed consent.\n\nExclusion Criteria:\n\n(1) Lymph node BulkyN2 status was diagnosed by abdominal CT\u002FMRI, that is, at least one lymph node meridian ≥3cm or three consecutive lymph nodes, each meridian ≥1.5cm;(2) pregnant or lactating women;(3) Other malignant tumors within 5 years;(4) Preoperative temperature ≥38℃ or complicated with infectious diseases requiring systematic treatment;(5) serious mental illness;(6) Severe respiratory diseases, FEV1\\\u003C 50%;(7) Severe liver and kidney dysfunction, liver enzyme elevation more than 2 times the normal value;(8) History of unstable angina pectoris or myocardial infarction within 6 months;(9) History of cerebral infarction or cerebral hemorrhage within 6 months, except old infarct;(10) Systemic glucocorticoid therapy within 1 month;(11) Patients with gastric cancer complications (bleeding, perforation, obstruction) requiring emergency surgery;(12) The patient has participated in or is currently participating in other clinical studies (within 6 months);(13) Laparoscopic exploration, biopsy and cytology confirmed intraperitoneal implantation and metastasis.","80 Years",{"count":189,"type":22},616,[191],"PHASE3","The goal of this clinical trial is to learn about Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer after Laparoscopic Gastrectomy with D2 Lymphadenectomy. The main question it aims to answer is: whether HIPEC can effectively improving the 5-year overall survival rate and decrease the peritoneal metastases rate of patients with advanced gastric cancer underwent Laparoscopic Gastrectomy with D2 Lymphadenectomy. Participants will be divided into two groups, Experimental group received laparoscopic (robotic) D2 surgery plus HIPEC2 times plus systemic chemotherapy 6\\~8 cycles; and Control group received laparoscopic (robotic) D2 surgery plus systemic chemotherapy 6\\~8 cycles.",[194],"Gastric Cancer",[196,197,198,199,200],"Advanced Gastric Cancer","HIPEC","Laparoscopic Gastrectomy","Randomized Clinical Trial","Recurrence-free survival","2026-03-04",{"date":174,"type":40},{"date":204,"type":40},"2022-11-20",{"date":206,"type":22},"2030-12",{"name":46,"class":47},{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":23,"phases":217,"briefSummary":218,"conditions":219,"keywords":222,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":230,"leadSponsor":232,"locationsCount":126},"100627833","safety-and-efficacy-of-small-extracellular-vesicles-nebulizer-in-patients-with-allergic-rhinitis-complicated-with-asthma-100627833","NCT07453771","Safety and Efficacy of Small Extracellular Vesicles Nebulizer in Patients With Allergic Rhinitis Complicated With Asthma","Safety and Preliminary Efficacy of Small Extracellular Vesicles (Code: hUC-MSC-sEV-002) Nebulizer in Patients With Allergic Rhinitis Complicated With Asthma: A Multicenter, Prospective, Randomized, Double-Blind Phase I\u002FII Clinical Study","Inclusion Criteria:\n\n1. Aged 18-60 years, regardless of gender;\n2. Patients with moderate to severe allergic rhinitis (with sleep\u002Fwork\u002Fstudy\u002Fdaily activity impairment or distressing symptoms) meeting the diagnostic criteria of the international Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines, positive for at least one inhalant allergen skin prick test, and concurrent asthma complying with the Global Initiative for Asthma (GINA) 2022 guidelines;\n3. Suboptimal response to antiallergic medication treatment for one year prior to enrollment;\n4. Patients who decline allergen-specific immunotherapy, or have no available specific therapy for the relevant allergen, or failed allergen-specific immunotherapy;\n5. Females of childbearing potential must agree to avoid pregnancy during study participation and for 30 days after the final visit;\n6. Subjects or their legal representatives must be able to sign the informed consent form and comply with the study requirements for medication administration and follow-up.\n\nExclusion Criteria:\n\n1. Complicated with other nasal and sinus diseases that may affect the reasonable assessment of efficacy and\u002For safety;\n2. Suffering from uncontrolled asthma or poorly controlled asthma symptoms;\n3. Suffering from malignant tumors, severe immune diseases, long-term use of immunosuppressants, or immunodeficiency;\n4. Having unstable conditions due to respiratory tract infection and\u002For acute asthma exacerbation within 4 weeks prior to the initial screening visit;\n5. Currently receiving treatment with beta-blockers or angiotensin-converting enzyme (ACE) inhibitors;\n6. Suffering from mental illnesses;\n7. Suffering from severe systemic diseases, such as cases of peptic ulcers, diabetes mellitus, and heart failure;\n8. Specific infections such as syphilis, leprosy, and tuberculosis;\n9. Females who are currently pregnant, planning to become pregnant soon, or breastfeeding;\n10. Patients who are currently participating in other clinical trials or have participated in other clinical trials within 30 days prior to the initial screening visit;\n11. Patients who are currently receiving allergen desensitization therapy or biologic therapy;\n12. Positive for hepatitis B surface antigen, hepatitis C virus antibody, syphilis serological antibody, or human immunodeficiency virus (HIV) antibody;\n13. In addition to the above conditions, patients will be excluded if the investigators consider them unsuitable for participation in this clinical study for other reasons.","60 Years",{"count":21,"type":22},[87],"This trial aims to evaluate the safety, tolerability and efficacy of hUC-MSC-sEV-002 nebulizer in patients with allergic rhinitis and asthma. It consists of two parts: ① Single-center dose exploration (The Affiliated Hospital of Qingdao University): A 3+3 escalation design will test three doses (1×10⁸, 1×10⁹, 1×10¹⁰ particles\u002FmL) to determine the maximum tolerated dose (MTD).Three subjects will be enrolled in each dose group. If no Dose-Limiting Toxicity (DLT) is observed among the 3 subjects, the study may proceed to the next dose exploration. If 1 out of the 3 subjects experiences DLT, an additional 3 subjects will be enrolled in the same dose group; the study may move to the next dose exploration only if no DLT is observed in these additional 3 subjects. If more than 1 out of the 3 subjects develops DLT, the previous dose group will be defined as the MTD. A total of at least 9 and at most 18 subjects will be recruited for this clinical trial. ② Multi-center case expansion: Participants will be randomized 2:1 to hUC-MSC-sEV-002 or placebo groups for efficacy comparison.Eligibility criteria: 18-60 years old; moderate-to-severe allergic rhinitis (ARIA guidelines) with positive inhaled allergen skin test; asthma diagnosed per GINA 2022; signed informed consent.Intervention: Nebulization once daily (5 times\u002Fweek, 2 weeks, 10 doses total). Follow-up visits at baseline, Week 2, 4, 12, 24, including symptom scales, lung function tests, nasal endoscopy, nasal exhaled nitric oxide test, chest X-ray, blood tests, and electrocardiogram. The trial is approved by the Medical Ethics Committee of The Affiliated Hospital of Qingdao University (No. QYFYEC2025-192). Participants may withdraw anytime without affecting medical care. Study period: Aug 2025-Aug 2027. Sample size: 9-18 for Part 1; Part 2 size based on Part 1 results.",[220,221],"Allergic Rhinitis","Asthma",[223,224,225,221,226],"Small extracellular vesicles","Nebulizer formulation","Allergic rhinitis","Randomized, double-blind","2026-02-27",{"date":174,"type":40},{"date":172,"type":22},{"date":231,"type":22},"2027-08-31",{"name":46,"class":47},{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":187,"enrollmentInfo":241,"targetDuration":4,"studyType":243,"phases":4,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":254,"locationsCount":48},"100620071","rapamycin-eluting-vertebral-stents-in-the-real-world-treatment-of-symptomatic-intracranial-atherosclerotic-stenosis-100620071","NCT07352852","Rapamycin-Eluting Vertebral Stents In The Real-World Treatment of Symptomatic Intracranial Atherosclerotic Stenosis","Rapamycin-eluting Vertebral Stents in the Real-world Treatment of Symptomatic Intracranial Atherosclerotic Stenosis","BRIDGE-INTRA","Inclusion Criteria:\n\n* Age ≥18 and ≤80 years;\n* Symptomatic intracranial atherosclerotic stenosis patients with ineffective medical treatment;\n* Digital subtraction angiography (DSA) shows target lesion stenosis ≥70%;\n* Suitable for implantation of rapamycin-targeted drug-eluting stents;\n* The patient and\u002For their authorized representative can understand the study purpose, agree to participate, and sign the informed consent form.\n\nExclusion Criteria:\n\n* Modified Rankin Scale (mRS) score ≥3;\n* Ischemic stroke within the past 2 weeks;\n* Presence of more than 2 intracranial atherosclerotic stenosis lesions requiring interventional treatment;\n* Severe contraindications to heparin, aspirin, ticagrelor, clopidogrel, or other antiplatelet drugs, and inability to tolerate anticoagulant\u002Fantiplatelet therapy;\n* Severe dysfunction of major organs (e.g., severe hepatic insufficiency, renal insufficiency, heart failure);\n* Severe allergies to contrast agents, rapamycin and its derivatives, cobalt-based alloys, or polylactic acid;\n* Pregnant or lactating women;\n* Participation in other drug or device studies without reaching the endpoint;\n* Life expectancy less than 12 months;\n* Lesions or vascular access deemed unsuitable for rapamycin drug-eluting stent implantation by the operator.",{"count":242,"type":22},300,"OBSERVATIONAL","This clinical trial is a prospective, multicenter, single-arm study. About 300 subjects undergoing rapamycin-eluting stent implantation will be enrolled based on the inclusion and exclusion criteria. The primary endpoint is the rate of any stroke or death within 1 month. Secondary efficacy endpoints include immediate stent implantation success. Safety endpoints cover the incidence of stroke or neurological death, target-vessel-related stroke or death, all-cause mortality, and mRS scores at 12-month follow-ups. Subjects will be clinically followed up before surgery, device implantation, discharge, and at 1, 6, and 12 months post-surgery. An imaging subgroup of at least 80 subjects who agree to DSA follow-up at 12 months will assess in-stent restenosis (\\>50%).",[246,247],"Intracranial Arterial Stenosis","Brain Diseases","2026-01-13",{"date":250,"type":40},"2026-01-20",{"date":252,"type":40},"2025-05-14",{"date":124,"type":22},{"name":46,"class":47},{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":263,"targetDuration":4,"studyType":23,"phases":265,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":48},"100602597","real-time-diagnosis-of-eosinophilic-nasal-polyps-using-high-sensitivity-spectroscopy-100602597","NCT07125586","Real-Time Diagnosis of Eosinophilic Nasal Polyps Using High-Sensitivity Spectroscopy","Evaluation of Efficacy and Safety of a Real-time Typing Diagnosis System for Eosinophilic Nasal Polyps Based on High-sensitivity Spectroscopy Technology","REDENP","Inclusion Criteria:\n\n1. Male and female subjects aged 18 to 65 years old\n2. Subjects diagnosed with CRSwNP by nasal endoscopy, CT, or MRI preoperatively (in accordance with the diagnostic criteria of EPOS 2020)\n3. Normal coagulation function (prothrombin time \\[PT\\], activated partial thromboplastin time \\[APTT\\], and platelet count are within the normal range)\n4. No severe cardiopulmonary dysfunction or other comorbidities that affect the tolerance of general anesthesia and surgery\n5. Women of childbearing age must take appropriate medical contraceptive measures during the study period and within 4 weeks after the end of the trial treatment\n6. Patients with good compliance, who voluntarily participate in this clinical study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with other nasal and paranasal sinus diseases excluding chronic rhinosinusitis (such as nasal tumors, fungal sinusitis, and post-traumatic nasal deformities)\n2. Patients with coagulation dysfunction, immunodeficiency, or long-term use of anticoagulant\u002Fantiplatelet drugs at the time of visit, and females during menstruation\n3. Patients who have taken oral glucocorticoids within 1 month prior to the visit\n4. Patients with a history of nasal endoscopic surgery or nasal radiotherapy\n5. Pregnant or lactating women, or those with severe systemic diseases (such as uncontrolled hypertension, diabetes, hepatic or renal insufficiency)\n6. Patients with incomplete clinical data or missing postoperative follow-up data\n7. Any other conditions deemed by the researcher as making the subject unsuitable for participating in the trial\n8. Patients with poor treatment compliance",{"count":264,"type":22},353,[87],"Chronic rhinosinusitis with nasal polyps (CRSwNP) is a common condition causing nasal congestion, discharge, and reduced sense of smell, seriously affecting patients' quality of life. A subtype called eosinophilic CRSwNP (eCRSwNP) is difficult to treat and often recurs after surgery.\n\nCurrently, diagnosing this subtype requires tissue samples after surgery, which delays treatment decisions and may lead to unnecessary surgeries. Our research team has developed a new, non-invasive diagnostic system using advanced spectral technology to detect a natural fluorescence marker inside eosinophils (a type of immune cell) in nasal polyps. This system can quickly identify eCRSwNP before surgery by shining a safe light on the nasal tissue and analyzing the fluorescence signals.\n\nThis study aims to evaluate how accurate and safe this real-time diagnostic system is in clinical practice. If successful, it will help doctors choose better personalized treatments, reduce unnecessary surgeries, lower recurrence rates, and ultimately improve patients' lives.",[268],"Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)","2025-12-23",{"date":271,"type":40},"2025-12-30",{"date":273,"type":40},"2025-08-26",{"date":275,"type":22},"2028-06-01",{"name":46,"class":47},{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":17,"minAge":284,"maxAge":109,"enrollmentInfo":285,"targetDuration":4,"studyType":23,"phases":286,"briefSummary":287,"conditions":288,"keywords":290,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":48},"100612207","a-randomized-trial-of-annular-repair-with-discectomy-versus-discectomy-alone-for-lumbar-disc-herniation-100612207","NCT07250581","A Randomized Trial of Annular Repair With Discectomy Versus Discectomy Alone for Lumbar Disc Herniation","Endoscopic Discectomy With Repair of Annulus Fibrosus Versus Discectomy Alone for Lumber Disc Herniation:A Prospective Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age: 12 years old to 65 years old, gender not limited;\n2. Diagnosed with Lumbar disc herniation;\n3. Preoperative intervertebral disc MRI Pfirrmann grade I - II;\n4. Conservative treatment is ineffective, and the symptoms significantly affect life;\n5. Be able to cooperate with long-term follow-up and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Accompanied by lumbar spondylolisthesis, lumbar instability and other lumbar diseases, etc.\n2. Previous history of lumbar spine surgery;\n3. Those who have other major physical diseases and are unable to tolerate surgery;\n4. Diseases such as malnutrition, abnormal bone metabolism, and autoimmune diseases that may affect the postoperative development process;\n5. Unable to accept regular follow-up visitors","12 Years",{"count":242,"type":22},[87],"The goal of this study is to explore the indications and application scope of spinal endoscopy combined with annulus fibrosus repair technology, with a focus on verifying the effectiveness of annulus fibrosus suture technology and evaluating its safety, so as to further support the promotion of annulus fibrosus repair technology in patients with lumbar disc herniation.",[289],"Lumbar Intervertebral Disc Herniation",[291,292,293],"Annulus fibrosus repair","Lumbar intervertebral disc herniation","Spinal endoscopy","2025-11-23",{"date":296,"type":40},"2025-11-26",{"date":298,"type":40},"2025-08-01",{"date":300,"type":22},"2026-12-31",{"name":46,"class":47},{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":187,"enrollmentInfo":309,"targetDuration":4,"studyType":23,"phases":311,"briefSummary":312,"conditions":313,"keywords":316,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":48},"100607038","family-supervised-prehabilitation-to-reduce-postoperative-complications-after-neoadjuvant-chemotherapy-in-gastric-cancer-100607038","NCT07183358","Family-Supervised Prehabilitation to Reduce Postoperative Complications After Neoadjuvant Chemotherapy in Gastric Cancer","Effect of Family-Supervised Multimodal Prehabilitation Throughout Preoperative Neoadjuvant Chemotherapy on Clinical Outcomes in Gastric Cancer Patients: A Single-Center Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18-80 years\n* Histologically proven gastric adenocarcinoma by gastroscopy\n* Clinical stage T2-4a, N any, M0 planned for neoadjuvant chemotherapy plus radical gastrectomy\n* ECOG performance status 0-1; ASA class I-III\n* Able to understand the study and provide signed informed consent\n\nExclusion Criteria:\n\n* Previous or concurrent malignancies\n* Emergent conditions (bleeding, perforation, obstruction) requiring immediate surgery\n* Pregnant or lactating women\n* Severe psychiatric disorders\n* Prior major abdominal surgery (except laparoscopic cholecystectomy)\n* Unstable angina, myocardial infarction, or cerebrovascular event within 6 months\n* Continuous use of NSAIDs, corticosteroids, or probiotics within 1 month\n* Simultaneous surgery for other diseases\n* FEV1 \\\u003C 50 % predicted\n* Any condition that, in the investigator's opinion, contraindicates participation",{"count":310,"type":22},90,[87],"This study evaluates whether a family-supervised exercise-nutrition-psychology program can reduce complications after stomach-cancer surgery. Eligible patients are adults who will receive chemotherapy before surgery. Participants are randomly assigned to either the multimodal prehabilitation program plus usual care or usual care alone. The main outcome is the rate of serious complications within 30 days after surgery. Potential benefits include fewer complications and faster recovery; risks are minimal and mainly related to mild exercise fatigue.",[314,315],"Stomach Neoplasms","Neoadjuvant Therapy",[317,318,319,320,321],"prehabilitation","postoperative complications","multimodal","family-supervised","gastric cancer","2025-09-13",{"date":324,"type":40},"2025-09-19",{"date":326,"type":22},"2025-09-20",{"date":328,"type":22},"2026-06-20",{"name":46,"class":47},{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":337,"targetDuration":4,"studyType":23,"phases":339,"briefSummary":340,"conditions":341,"keywords":344,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":48},"100604697","phase-4-the-effects-of-clostridium-butyricum-on-adverse-events-during-adjuvant-chemotherapy-for-colorectal-cancer-100604697","NCT07152886","The Effects of Clostridium Butyricum on Adverse Events During Adjuvant Chemotherapy for Colorectal Cancer","The Effects of Clostridium Butyricum on Adverse Events During Adjuvant Chemotherapy for Colorectal Cancer: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Aged 18-70 years;\n* No restriction on gender;\n* Have completed radical resection for colorectal cancer (including open, laparoscopic, or robotic surgery), and assessed by the MDT as requiring adjuvant therapy primarily based on 5-FU and its derivatives or platinum-based regimens (including chemotherapy, targeted therapy, or radiotherapy);\n* ECOG performance status score of 0-2;\n* Signed informed consent\n\nExclusion Criteria:\n\n* Use of probiotics, prebiotics, synbiotics, or antibiotics within 2 weeks prior to enrollment;\n* Presence of psychiatric disorders or other conditions that prevent cooperation with the intervention;\n* Dysfunction of vital organs such as the liver, kidneys, or heart that renders the individual unsuitable for clinical research upon assessment, or inadequate bone marrow, liver, or renal function to undergo adjuvant therapy;\n* Participation in other clinical studies within 3 months prior to enrollment;\n* History of inflammatory bowel disease;\n* History of autoimmune diseases;\n* Pregnancy or breastfeeding;\n* Receipt of neoadjuvant therapy (including chemotherapy, radiotherapy, or targeted therapy) prior to surgery;\n* Underwent ostomy surgery during the operation (including temporary or permanent ostomy).",{"count":338,"type":22},238,[60],"This study is a multicenter randomized controlled trial designed to investigate the effects of Clostridium butyricum on adverse events during adjuvant treatment for colorectal cancer.",[342,343],"Colorectal Cancer","Chemotherapeutic Toxicity",[342,345,66],"adjuvant chemotherapy",{"date":347,"type":40},"2025-09-03",{"date":349,"type":22},"2025-10-31",{"date":351,"type":22},"2027-12-31",{"name":46,"class":47},{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":187,"enrollmentInfo":360,"targetDuration":4,"studyType":23,"phases":362,"briefSummary":363,"conditions":364,"keywords":367,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":380,"locationsCount":48},"100603618","the-intraoperative-technical-errors-of-robotic-vs-laparoscopic-radical-right-hemiclectomy-100603618","NCT07138859","The Intraoperative Technical Errors of Robotic vs. Laparoscopic Radical Right Hemiclectomy","Prospective, Multiceter, Randomized, Controlled Study on the Intraoperative Technical Errors of Robotic vs. Laparoscopic Radical Right Hemiclectomy (Superiority Design，ROBOGEON® 2501study)","Inclusion Criteria:\n\n1. 18 years old\\\u003Cage\\\u003C80 years old, regardless of gender;\n2. The primary lesion of the colon was diagnosed as colon adenocarcinoma (well differentiated adenocarcinoma, moderately differentiated adenocarcinoma, poorly differentiated adenocarcinoma, mucinous adenocarcinoma) through endoscopic biopsy tissue pathology;\n3. The preoperative clinical staging was cStage I-III (cT1-4a, N0\u002F+, M0) (according to UICC\u002FAJCC-8thTNM tumor staging);\n4. The primary lesions of the colon are located in the cecum, ascending colon, hepatic flexure of the colon, and right half of the transverse colon. It is expected that right-sided colectomy and D3 lymph node dissection can achieve R0 surgical results (excluding multiple primary cancers);\n5. Preoperative examination showed no distant metastasis, and the tumor did not directly invade adjacent organs;\n6. Preoperative ECOG physical status score ≤ 2;\n7. Preoperative ASA scores I-III;\n8. Patient informed consent.\n\nExclusion Criteria:\n\n1. History of colon surgery (excluding ESD\u002FEMR for colon cancer);\n2. History of major abdominal surgery (excluding laparoscopic cholecystectomy and appendectomy);\n3. Preoperative body temperature ≥ 38 ℃ or complicated with infectious diseases requiring systematic treatment;\n4. Pregnant or lactating women;\n5. Suffering from severe mental illness;\n6. Multiple primary cancers;\n7. History of other malignant diseases within 5 years;\n8. Any neoadjuvant therapy such as chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc. has been implemented;\n9. History of unstable angina or myocardial infarction within 6 months;\n10. Heart, lung, liver, kidney dysfunction or history of cerebral infarction;\n11. Simultaneous surgical treatment is required for other diseases;\n12. Colorectal cancer complications (bleeding, perforation, obstruction) require emergency surgery.",{"count":361,"type":22},368,[87],"Experimental design: This study is a multicenter, prospective, randomized, controlled phase III clinical trial that identifies, classifies, defines, and quantitatively analyzes technical errors between robotic and laparoscopic radical right hemicolectomy (D3 lymph node dissection), identifies surgical risk areas, compares intraoperative performance, and patient short-term and long-term clinical outcomes.\n\nThis experimental design was based on a 1:1 effective target case ratio between the experimental group and the control group for enrollment. The experimental group underwent robotic radical right hemicolectomy (D3 lymph node dissection), while the control group underwent laparoscopic radical right hemicolectomy (D3 lymph node dissection). The unedited surgical videos of patients were analyzed, and relevant indicators and adverse events were recorded. Patients were followed up in the outpatient department after discharge until 3 years after surgery or until death or recurrence.\n\nSample size calculation: In this study, the calculation of sample size was based on pre experiments and hypotheses, and a goodness test was conducted by selecting the means of two independent samples. Referring to the results of the pilot study, based on a 1:1 random (random number table method) ratio, assuming a significance level of unilateral α=0.025, a test power of 1- β=80%, and a superiority margin of 20% in reducing the number of errors, and considering the maximum dropout rate of 0.1 in this clinical study, the total sample size for this study was determined to be 368 patients (184 in the RRC group and 184 in the LRC group).\n\nPrimary endpoint: incidence of technical errors during right hemicolectomy. Secondary endpoint: incidence of intraoperative complications; The incidence of complications within 30 days after surgery; Total surgical time, robot\u002Flaparoscope time; Estimate the amount of blood loss; Conversion to open surgery rate; Postoperative hospitalization time; Total number of lymph nodes cleared and positive rate of lymph nodes; Early postoperative recovery process (time of first defecation and defecation); 30 day readmission rate and unplanned reoperation rate after surgery; Postoperative nutritional status, inflammation, and immune response; 3-year disease-free survival rate DFS; 3-year overall survival rate (OS).\n\nInclusion criteria: 1) 18 years old\\\u003Cage\\\u003C80 years old, regardless of gender; 2) The primary lesion of the colon was diagnosed as colon adenocarcinoma (well differentiated adenocarcinoma, moderately differentiated adenocarcinoma, poorly differentiated adenocarcinoma, mucinous adenocarcinoma) through endoscopic biopsy tissue pathology; 3) The preoperative clinical staging was cStage I-III (cT1-4a, N0\u002F+, M0) (according to UICC\u002FAJCC-8thTNM tumor staging); 4) The primary lesions of the colon are located in the cecum, ascending colon, hepatic flexure of the colon, and right half of the transverse colon. It is expected that right-sided colectomy and D3 lymph node dissection can achieve R0 surgical results (excluding multiple primary cancers); 5) Preoperative examination showed no distant metastasis, and the tumor did not directly invade adjacent organs; 6) Preoperative ECOG physical status score ≤ 2; 7) Preoperative ASA scores I-III; 8) Patient informed consent.\n\nExclusion criteria: 1) History of colon surgery (excluding ESD\u002FEMR for colon cancer); 2) History of major abdominal surgery (excluding laparoscopic cholecystectomy and appendectomy); 3) Preoperative body temperature ≥ 38 ℃ or complicated with infectious diseases requiring systematic treatment; 4) Pregnant or lactating women; 5) Suffering from severe mental illness; 6) Multiple primary cancers; 7) History of other malignant diseases within 5 years; 8) Any neoadjuvant therapy such as chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc. has been implemented; 9) History of unstable angina or myocardial infarction within 6 months; 10) Heart, lung, liver, kidney dysfunction or history of cerebral infarction; 11) Simultaneous surgical treatment is required for other diseases; 12) Colorectal cancer complications (bleeding, perforation, obstruction) require emergency surgery.",[365,366],"Colorectal Carcinoma (CRC)","Right Hemicolectomy",[365,368,369,370,371,372,373],"right hemicolectomy","Robotic surgery","Errors","Intraoperative bleeding","Dangerous areas","Clinical outcome","2025-08-17",{"date":376,"type":40},"2025-08-24",{"date":378,"type":22},"2025-08",{"date":206,"type":22},{"name":46,"class":47},{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":187,"enrollmentInfo":387,"targetDuration":4,"studyType":243,"phases":4,"briefSummary":388,"conditions":389,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":397,"leadSponsor":398,"locationsCount":48},"100602968","multimodal-imaging-assessment-after-revascularization-in-patients-with-acute-myocardial-infarction-100602968","NCT07130409","Multimodal Imaging Assessment After Revascularization in Patients With Acute Myocardial Infarction","Inclusion Criteria:\n\n* Patients with a clinical diagnosis of first-episode acute myocardial infarction (AMI) who underwent emergency percutaneous coronary intervention (PCI) were included. All patients had complete baseline clinical data, with baseline cardiac magnetic resonance (CMR) examinations performed within 7 days post-PCI and follow-up CMR completed at 6 months post-procedure.\n\nExclusion Criteria:\n\n* Patients with severe cardiac decompensation (Killip class 4) or clinically unstable conditions.\n\nPatients with coexisting valvular heart disease, congenital heart disease, pulmonary hypertension, cardiomyopathy, or persistent atrial fibrillation that may confound cardiac structural\u002Ffunctional assessments.\n\nPrior history of myocardial infarction, coronary revascularization (PCI\u002FCABG).\n\nConcurrent severe systemic diseases including hematologic disorders, malignancies, rheumatic\u002Fautoimmune diseases, or severe hepatic\u002Frenal failure.\n\nContraindications to CMR (claustrophobia, pacemaker implantation, etc.).\n\nPregnant, breastfeeding, or women of childbearing potential without effective contraception.\n\nSexually active individuals of reproductive age unwilling to use reliable contraception.",{"count":134,"type":22},"This prospective cohort study will enroll 20 patients clinically diagnosed with first-time acute myocardial infarction (AMI) who underwent interventional procedures (including percutaneous coronary intervention \\[PCI\\] and balloon angioplasty) at the Affiliated Hospital of Qingdao University. Patient data, including routine blood and urine tests, blood biochemistry, electrocardiograms (ECG), imaging studies, and interventional procedure records, will be collected to assess eligibility for enrollment. The study procedures include patient screening and enrollment, obtaining informed consent, baseline assessment (including medical history, laboratory tests, ECG, etc.), an ¹⁸F-Pentixafor PET\u002FMR examination, and follow-up. Images will be blindly assessed by at least two specialized physicians from the Radiology and Nuclear Medicine departments. The study aims to investigate the utility of ¹⁸F-Pentixafor PET\u002FMR in evaluating coronary microcirculatory function, cardiac function, myocardial viability, myocardial inflammatory response, and the efficacy of interventional therapy in AMI patients post-procedure. Additionally, it will perform risk stratification and prognostic analysis for the enrolled patients.",[390,391,392],"Cardiac Magnetic Resonance Imaging","Acute Myocardial Infarction (AMI)","PET \u002F MR","2025-08-15",{"date":395,"type":40},"2025-08-19",{"date":378,"type":22},{"date":300,"type":22},{"name":46,"class":47},{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":187,"enrollmentInfo":405,"targetDuration":4,"studyType":243,"phases":4,"briefSummary":407,"conditions":408,"keywords":412,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":48},"100601240","multimodal-imaging-assessment-of-chronic-kidney-disease-patients-at-different-stages-from-a-cardio-renal-interaction-perspective-100601240","NCT07107919","Multimodal Imaging Assessment of Chronic Kidney Disease Patients at Different Stages From a Cardio-Renal Interaction Perspective","Inclusion Criteria:\n\n1. Age between 18 and 80 years, regardless of sex.\n2. Clinically diagnosed with chronic kidney disease (CKD), based on KDIGO guidelines.\n3. Complete clinical data available.\n4. Written informed consent for participation and for undergoing 18F-FAPI PET\u002FMR imaging is obtained from the patient or their legal guardian.\n5. Female participants must agree to use effective contraception during the study and for at least 6 months after its completion (e.g., sterilization, intrauterine hormonal devices, condoms, hormonal contraceptives, abstinence, or vasectomized partner). Male participants must also agree to use contraception during the study and for 6 months after its completion.\n\nExclusion Criteria:\n\n1. Women who are planning to conceive, currently pregnant, or breastfeeding.\n2. Contraindications to PET\u002FMR imaging, including but not limited to metal implants, claustrophobia, or inability to tolerate cardiac MRI due to respiratory difficulties.\n3. History of allergy or hypersensitivity to gadolinium-based contrast agents.\n4. Presence of malignant tumors or other serious progressive diseases.\n5. Patients with severe cardiac conditions, such as advanced heart failure, severe valvular disease, or cardiomyopathies.\n6. Hemodynamic instability.\n7. Presence of severe systemic or localized infections, or other serious comorbid conditions.\n8. Incomplete clinical data.\n9. Any other reason deemed by the investigators to make the subject unsuitable for participation, including inability or unwillingness to comply with study procedures and requirements.\n10. Determined by the investigators to be inappropriate for inclusion in the study.",{"count":406,"type":22},60,"This study is a prospective cohort investigation in which consecutive eligible patients undergo 18F-FAPI PET\u002FMR imaging. Chronic kidney disease (CKD) participants are stratified into two groups:Group I ：CKD stages 1-3（eGFR ≥ 30 mL\u002Fmin\u002F1.73 m²）,Group II :CKD stages 4-5(eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n\nUsing 18F-FAPI PET\u002FMR, we will evaluate global cardiac functional impairment and myocardial fibrosis characteristics, and analyze their associations with the degree of renal dysfunction.",[409,410,411],"Chronic Kidney Disease","Cardiac Magnetic Resonance","18F-FAPI",[413,410,411],"CKD","2025-07-31",{"date":416,"type":40},"2025-08-06",{"date":418,"type":22},"2025-07-30",{"date":420,"type":22},"2027-06-01",{"name":46,"class":47},{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":17,"minAge":429,"maxAge":187,"enrollmentInfo":430,"targetDuration":4,"studyType":23,"phases":432,"briefSummary":433,"conditions":434,"keywords":439,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":4},"100595103","a-study-on-the-clinical-use-of-a-new-expandable-olif-cage-with-posterior-bone-grafting-in-lumbar-spine-surgery-100595103","NCT07028099","A Study on the Clinical Use of a New Expandable OLIF Cage With Posterior Bone Grafting in Lumbar Spine Surgery","Multi-Center Randomized Controlled Clinical Study on the Application of a Novel Expandable Posterior Bone Grafting OLIF Cage","Inclusion Criteria:1: Age between 40 and 80 years (inclusive)\n\n2: Clinically diagnosed with lumbar spondylolisthesis or lumbar spinal stenosis\n\n3: Confirmed single-level lumbar degenerative disease\n\n4: Affected level located at L2\u002F3, L3\u002F4, or L4\u002F5\n\n5: Failure of conservative treatment for at least 6 months\n\nExclusion Criteria:1: Patients requiring direct decompression of the spinal canal\n\n2: History of prior lumbar or retroperitoneal surgery\n\n3: Abnormal anatomy between the iliac vascular sheath and the psoas major muscle\n\n4: Presence of active infection or other significant systemic diseases\n\n5: Inability to complete surgical treatment or comply with follow-up due to various limitations\n\n\\-","40 Years",{"count":431,"type":22},340,[87],"This clinical trial aims to evaluate the safety and effectiveness of a novel expandable OLIF (Oblique Lateral Interbody Fusion) cage with posterior bone grafting in patients with lumbar degenerative diseases. OLIF is a minimally invasive spinal surgery technique that restores intervertebral height and relieves nerve compression by placing a cage into the disc space.\n\nThe new device allows surgeons to adjust the height of the cage during surgery and deliver bone grafts through a special channel after expansion. This study compares the outcomes of patients receiving the new cage versus those treated with a conventional OLIF cage.\n\nThe trial will assess pain relief, functional improvement, spinal stability, fusion success, and potential complications. Radiological images and patient-reported scores (like VAS and ODI) will be collected over 12 months. The study includes patients aged 40 to 80 with single-level lumbar spine disease who have not improved after at least 6 months of conservative treatment.\n\nThis study will help determine whether the new expandable cage offers clinical advantages and better long-term outcomes for patients undergoing OLIF surgery.",[435,436,437,438],"Lumbar Spondylolisthesis","Degenerative Lumbar Scoliosis","Lumbar Disc Herniation","Lumbar Spinal Stenosis",[440,441,442,443],"Expandable OLIF Cage","Minimally Invasive Spine Surgery","Prospective Multicenter Randomized Controlled Trial","Degenerative Lumbar Disease","2025-06-17",{"date":446,"type":40},"2025-06-19",{"date":448,"type":22},"2025-06-10",{"date":450,"type":22},"2027-05-31",{"name":46,"class":47},{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":458,"targetDuration":4,"studyType":243,"phases":4,"briefSummary":460,"conditions":461,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":48},"100586535","clinical-study-on-the-application-of-18f-her2-affibody-pet-imaging-in-her2-expressing-breast-cancer-100586535","NCT06916637","Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer","Inclusion Criteria:\n\n* Age 18-75 years, ECOG score 0 or 1.\n* Clinically or pathologically confirmed diagnosis of patients with HER2 expression breast cancer or suspected expression breast cancer.\n* Life expectancy ≥ 12 weeks.\n* At least one measurable target lesion according to RECIST 1.1 criteria.\n* All participants of reproductive potential (regardless of gender) must commit to using effective contraceptive methods throughout the trial participation and for 6 months after the last PET scan.\n* Ability to understand and voluntarily sign the informed consent form, with good compliance.\n\nExclusion Criteria:\n\n* Severe hepatic or renal dysfunction.\n* Pregnant or lactating women, or women planning to become pregnant.\n* Inability to lie supine for half an hour.\n* Refusal to participate in this clinical study.\n* Suffering from claustrophobia or other mental illnesses.\n* Other conditions that the investigator deems unsuitable for participation in the trial.",{"count":459,"type":22},40,"This study aims to evaluate the clinical utility of 18F-labeled HER2 Affibody PET for diagnosing and monitoring HER2-expressing breast cancer. HER2, a protein overexpressed in certain malignancies including breast cancer, serves as a critical biomarker for targeted therapies.The HER2 Affibody-an engineered 7 kDa protein with nanomolar affinity for HER2-leverages its rapid tumor penetration and clearance kinetics to achieve high-contrast PET imaging. This study aims to evaluate the diagnostic efficacy of 18F-HER2 Affibody PET in early detection, clinical staging, and treatment response monitoring, thereby providing novel imaging evidence to guide personalized therapeutic strategies for patients with HER2-expressing breast cancer.",[462,463],"Breast Cancer","Breast Cancer, HER2-Expression","2025-04-27",{"date":466,"type":40},"2025-04-30",{"date":468,"type":40},"2025-04-09",{"date":470,"type":22},"2027-12",{"name":46,"class":47},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":478,"targetDuration":4,"studyType":243,"phases":4,"briefSummary":479,"conditions":480,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":48},"100586534","multicenter-study-of-18f-labeled-ny104-for-petct-imaging-in-renal-cell-carcinoma-100586534","NCT06916624","Multicenter Study of 18F-Labeled NY104 for PET\u002FCT Imaging in Renal Cell Carcinoma","Inclusion Criteria:\n\n* (1)Capable of understanding and voluntarily signing the informed consent form; able to complete the trial in accordance with the protocol requirements; (2)Age 18-75 years; no gender restrictions; (3)Clinically diagnosed\u002Fsuspected as renal cell carcinoma or clinically diagnosed\u002Fsuspected recurrence\u002Fmetastasis after RCC treatment; (4)At least 1 measurable solid lesion in the subject, which can be accurately and continuously measured using modified RECIST criteria (version 1.1); (5)ECOG performance status score of 0-2; (6)Laboratory parameters must meet:\n\n  1. Hematology: WBC ≥4.0×10⁹\u002FL or neutrophils ≥1.5×10⁹\u002FL, PLT ≥100×10⁹\u002FL, Hb ≥90g\u002FL; PT or APTT ≤1.5×ULN (upper limit of normal);\n  2. Liver and kidney function: T-Bil ≤1.5×ULN, ALT\u002FAST ≤2.5×ULN or ≤5×ULN (for subjects with liver metastasis), ALP ≤2.5×ULN (if bone or liver metastasis present, ALP ≤4.5×ULN); BUN ≤1.5×ULN, SCr ≤1.5×ULN;\n  3. Other routine tests within normal ranges or deemed acceptable by the investigator; (7)Expected survival ≥12 weeks; (8) Female subjects: Effective contraception (defined as sterilization, intrauterine hormone device, condoms, contraceptives\u002Fagents, abstinence, or partner vasectomy) must be used during the study and for 6 months post-study; Male subjects: Agreement to use contraception during the study and for 6 months post-study.\n\nExclusion Criteria:\n\n1. Recovery from major trauma (including surgery) within 4 weeks prior to study examination;\n2. Patients with systemic or local severe infections or other serious comorbidities;\n3. Severe hepatic or renal dysfunction;\n4. Refusal to participate in this clinical study;\n5. Patients with a history of allergy to any component of the imaging agent (including antibodies) or allergic constitution;\n6. Childbearing-aged male or female subjects who cannot adopt effective contraception;\n7. Women planning pregnancy, currently pregnant, or lactating;\n8. Patients unable or unwilling to undergo PET\u002FCT scanning;\n9. Other subjects deemed ineligible by the investigator.",{"count":459,"type":22},"Study on the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 18F-NY104 PET\u002FCT in diagnosing primary, recurrent, and metastatic lesions of renal cell carcinoma; and investigate the effect of oral low-dose CAIX inhibitor (Acetazolamide) on the tissue distribution of 18F-NY104 in renal cell carcinoma patients, particularly in the stomach and kidneys.",[481,482],"Renal Cell Carcinoma (RCC)","Clear Cell Renal Cell Carcinoma (ccRCC)",{"date":484,"type":40},"2025-04-29",{"date":486,"type":40},"2025-04-12",{"date":488,"type":22},"2026-12",{"name":46,"class":47},{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":496,"targetDuration":4,"studyType":243,"phases":4,"briefSummary":498,"conditions":499,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":500,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":504,"locationsCount":48},"100586512","clinical-study-of-18f-labeled-fapi-04-in-pet-imaging-of-breast-cancer-100586512","NCT06916338","Clinical Study of 18F-Labeled FAPI-04 in PET Imaging of Breast Cancer","Inclusion Criteria:\n\n1. Age 18-75 years old, any gender;\n2. Clinically or pathologically confirmed diagnosis of breast cancer, or suspected recurrence\u002Fmetastasis;\n3. Presence of at least 1 measurable lesion (RECIST 1.1 criteria);\n4. ECOG score 0-2 and expected survival ≥ 12 weeks;\n5. Laboratory markers are met:\n\n   Blood count: WBC ≥4.0×10⁹\u002FL, PLT ≥100×10⁹\u002FL, Hb ≥90 g\u002FL Liver and kidney function: ALT\u002FAST ≤ 2.5 × ULN, SCr ≤ 1.5 × ULN;\n6. Signed informed consent.\n\nExclusion Criteria:\n\n1. Major surgery or trauma within 4 weeks;\n2. Severe infection, liver or kidney insufficiency;\n3. History of allergies (developer components);\n4. Pregnant\u002Fnursing female or not using effective contraception;\n5. Inability to co-operate with PET (e.g. claustrophobia);\n6. Any other situation that researchers considered it unsuitable to participate in the trial.",{"count":497,"type":22},30,"This study aims to evaluate the diagnostic accuracy (sensitivity, specificity, positive\u002Fnegative predictive value, and overall accuracy) of 18F-FAPI-04 PET imaging in breast cancer for detecting fibroblast activation protein (FAP)-rich lesions. Additionally, the study will longitudinally monitor dynamic changes in FAP expression levels and tumor size during therapy, including chemotherapy, targeted therapy, or immunotherapy.The non-invasive nature of 18F-FAPI-04 PET addresses limitations of traditional biopsy-dependent stromal evaluation, offering whole-body quantification of tumor microenvironment dynamics to optimize therapeutic decision-making.",[462],{"date":484,"type":40},{"date":502,"type":40},"2025-04-11",{"date":470,"type":22},{"name":46,"class":47},{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":511,"sex":17,"minAge":429,"maxAge":109,"enrollmentInfo":512,"targetDuration":4,"studyType":23,"phases":514,"briefSummary":515,"conditions":516,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":48},"100574021","phase-1-a-single-center-open-randomized-single-dose-cross-over-bioequivalence-study-to-evaluate-the-effects-of-the-test-formulation-abalparatide-injection-and-the-reference-formulation-abalparatide-injection-tymlos-in-healthy-adult-subjects-100574021","NCT06753864","A Single-center, Open, Randomized, Single-dose, Cross-over Bioequivalence Study to Evaluate the Effects of the Test Formulation Abalparatide Injection and the Reference Formulation Abalparatide Injection (Tymlos®) in Healthy Adult Subjects","Inclusion Criteria:\n\n* 1\\. Before the test, voluntarily sign informed consent, fully understand the test content, process and possible adverse reactions, and complete the study according to the requirements of the test plan; 2. Female subjects have taken effective contraceptive measures within 14 days before the first dose (self-screening period for male subjects) and are willing to have no pregnancy, sperm donation or egg donation plan from signing informed to 6 months after the last dose, and voluntarily take effective contraceptive measures, specific contraceptive measures are shown in Appendix 2; 3. Male and female subjects aged 40 to 65 years (including boundary values); 4. Male subjects weigh no less than 50.0kg, female subjects weigh no less than 45.0kg, body mass index in the range of 19.0\\~28.0 kg\u002Fm2 (including the critical value).\n\nExclusion Criteria:\n\n* 1\\. Have a history of serious diseases such as heart, liver, kidney, digestive tract, nervous system, endocrine system, respiratory system and mental disorders, which are considered unsuitable by the study doctor; 2. Clinically significant abnormalities judged by clinicians, including physical examination, vital signs examination, electrocardiogram or clinical laboratory examination; 3. Currently suffering from allergic diseases (urticaria, asthma, etc.), or allergies (such as allergies to two or more drugs, foods such as milk or pollen), or known allergies to components or analogues of the drug; 4. Patients with hyperparathyroidism, Paget's disease or history; 5. Past or present postural hypotension or dizziness in the morning; 6. Hyperuricemia (including previous history of gout), hypercalcemia or active urinary calculus; 7. Serum calcium higher than the upper limit of normal, or creatinine clearance \\\u003C80mL\u002Fmin(calculation formula: male Ccr(mL\u002Fmin)= \\[(140- age)× body weight (kg)\\]\u002F\\[0.818× serum creatinine (μmol\u002FL)\\]; Ccr female =Ccr male ×0.85); 8. Patients who have previously received extra-skeletal beam or implanted radiation therapy; 9. Female subjects who are pregnant, breastfeeding or have positive pregnancy test results; 10. Hepatitis B surface antigen, hepatitis C antibodies, HIV antibodies or syphilis antibodies, any one or more of which are positive 11. Have a history of drug abuse within 5 years, or have used drugs within 3 months before screening, or urine drug screening is positive; 12. Those who consumed an average of more than 14 units of alcohol per week (1 unit =360mL beer or 45mL liquor with 40% alcohol or 150mL wine) in the 3 months prior to screening, or who could not stop alcohol intake from 24h before first dosing to the completion of all blood samples collected, or who tested positive for alcohol breath tests; 13. Those who smoked more than 5 cigarettes per day in the 3 months before screening or stopped using tobacco products during the period of refusal to stay; 14. Had a history of surgery within 3 months prior to screening, or planned to have surgery during the study period; 15. Those who donated blood or lost a lot of blood within 3 months before the first administration (\\>400mL, except for female physiologic blood loss), or donated platelets ≥2 therapeutic amounts (1 therapeutic amount =12U platelets) within 1 month; 16. Participants in any drug clinical trial and administration within 3 months before the first dose; 17. Those who have received any prescription drugs (including vaccines) within 14 days prior to the first dose; 18. Those who have received any over-the-counter medicines (including birth control pills), Chinese herbs or health products (including vitamins) within 7 days before the first dose; 19. ngested any food rich in xanthines (such as coffee, tea, chocolate, cocoa, milk tea, etc.), grapefruit (grapefruit), pomelo, pomegranate, lime, star fruit and its products, or had intense exercise, or other factors affecting drug absorption, distribution, metabolism, excretion, etc.; 20. Patients with difficulty in venous blood collection or a history of fainting needles and fainting blood, or skin scars, wounds or tattoos at the injection site, which affect the absorption or observer of injection drugs; 21. Subjects deemed unsuitable for participation by other investigators.",true,{"count":513,"type":22},32,[25],"To investigate the pharmacokinetics of the test preparation abalparatide injection and the reference preparation abalparatide injection (Tymlos®) in healthy adult subjects under fasting state, and to evaluate the bioequivalence of the two formulations under fasting state.",[517],"Osteoporosis","2024-12-23",{"date":520,"type":40},"2024-12-31",{"date":522,"type":22},"2025-01-02",{"date":524,"type":22},"2025-05-01",{"name":46,"class":47},{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":532,"minAge":18,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":23,"phases":535,"briefSummary":536,"conditions":537,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":48},"100568579","phase-1-study-on-human-bioequivalence-of-triprerelin-acetate-for-injection-100568579","NCT06683066","Study on Human Bioequivalence of Triprerelin Acetate for Injection","Inclusion Criteria:\n\n1\\. Voluntarily participate in the test, and sign the informed consent, and fully understand the test content, process and possible adverse reactions; 2. Male participants aged 18 years and older, male weight ≥50.0kg, body mass index (BMI) of 19 to 30kg\u002Fm2; 3. Patients with histopathologically diagnosed prostate cancer who were judged by investigators to be suitable for endocrine therapy, including 1 who had not received gonadotropin-releasing hormone analogues (GnRHa); 2 Patients receiving stable treatment with triprerelin acetate for injection; 3 Patients who have previously been treated with a gonadotropin-releasing hormone analogue (GnRHa) and who have been evaluated by the investigators as suitable for treatment with GNRHA; 4. ECOG score ≤2 points; 5. Expected survival ≥ 9 months; 6. Adequate hematopoietic function, liver and kidney function; 7. The subject is willing to have no family planning, sperm donation plan and voluntarily use one or more non-drug contraceptive methods (such as barrier contraception or abstinence) for 6 months from the signing of the information to the end of the drug administration.\n\n\\-\n\nExclusion Criteria:\n\n1\\. Patients who have previously undergone surgical castration; 2. Patients with known or suspected definite signs and symptoms of BMS or definite diagnosis of BMS; 3. Concurrent malignant tumors other than prostate cancer within 5 years, excluding basal cell carcinoma or squamous cell carcinoma of the skin that has been surgically removed; 4. Patients who have previously undergone adrenalectomy or pituitary resection or have pituitary disease; 5. Those who plan to undergo prostate surgery or other major surgical treatment during the study period (except urinary tract obstruction removal); 6. Patients with past or suspected spinal cord compression or urinary tract obstruction leading to kidney injury or patients at risk of developing such phenomena; 7. Patients with severe cardiovascular and cerebrovascular diseases, including but not limited to: patients with poorly controlled hypertension (systolic blood pressure \\>160 mmHg and\u002For diastolic blood pressure \\>100 mmHg under regular medication control); Patients with a history of hypertensive crisis or hypertensive encephalopathy; Severe cardiovascular and cerebrovascular disease, such as myocardial infarction, or heart failure classified by the New York Heart Association ≥II, within 6 months before the first administration of the investigational drug; Severe cardiac arrhythmia that cannot be controlled by medication (including QTc interval ≥470 ms), or congenital long QT syndrome; 8. Type I diabetes; Patients with type 2 diabetes with poor glycemic control (HbA1c\\>8.0% at screening); 9. Hepatitis B Surface antigen (HBsAg) test positive with HBV-DNA greater than 104copies\u002FmL(or 2000IU\u002FmL), or hepatitis C antibody positive with HCV-RNA test positive, or HIV antibody positive, Or syphilis antibody positive and RPR or TRUST positive; 10. Previous history of severe asthma or severe anaphylaxis or severe urticaria and\u002For vasogenic edema; 11. Persons known to be allergic to any component of triprerelin acetate for injection or to GnRH analogues; 12. People who are currently abusing drugs, drugs or alcohol (drinking an average of more than 14 units of alcohol per week, 1 unit =360 mL of beer or 45 mL of 40% alcohol spirits or 150 mL of wine); 13. A drug known to prolong the QT interval or induce tip torsive ventricular tachycardia (e.g., Class IA (e.g., quinidine, propylamine) or Class III (amiodarone, sotalol, dofetilide, ibutilide) was taken for 4 weeks or 5 half-lives (whichever is longer) prior to administration (including induction and trial) Psychotics, methadone, moxifloxacin, antipsychotics, etc; 14. Those who participate in other clinical trials and receive clinical trial drugs or devices within 1 month before administration (including the introduction period and the trial period); 15. Those who received any vaccine within 4 weeks prior to administration (including the introduction and trial period); 16. People who ingested special diet (such as grapefruit, pomelo and its products) within 48 hours before administration (including the introduction period and the trial period), or other factors that may affect drug absorption, distribution, metabolism, excretion and so on; 17. Those who donated blood or lost a large amount of blood (≥200mL) within 1 month before administration (including the introduction period and the trial period), and received blood transfusion or platelet transfusion ≥2 therapeutic amounts (1 therapeutic amount =12U platelet); 18. Patients with difficulty in venous blood collection; 19. Other circumstances in which the investigator considers it inappropriate to participate in the clinical trial, or in which the participant's participation in the trial may affect the trial results or his or her own safety.\n\n\\-","MALE",{"count":534,"type":22},120,[25],"To investigate the pharmacokinetics of triprerelin acetate for injection and triprerelin acetate (Dufferin ®) for injection of reference preparation in patients with prostate cancer by single intramusculodynamic injection in fasting state, and to evaluate the bioequivalence of the two formulations in fasting state.",[538],"Prostate Cancer (CRPC)","2024-11-08",{"date":541,"type":40},"2024-11-12",{"date":543,"type":22},"2024-12-04",{"date":545,"type":22},"2025-09-04",{"name":46,"class":47},{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":554,"enrollmentInfo":555,"targetDuration":4,"studyType":23,"phases":557,"briefSummary":558,"conditions":559,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":4},"100566023","comparison-of-the-clinical-efficacy-and-safety-of-endoscopic-superior-rectal-mucosal-ligation-and-hemorrhoids-ligation-100566023","NCT06649786","Comparison of the Clinical Efficacy and Safety of Endoscopic Superior Rectal Mucosal Ligation and Hemorrhoids Ligation","Comparison of the Efficacy and Safety of Endoscopic Hemorrhoids Ligation: a Single-center Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. According to the Goligher classification in the Chinese guidelines for the diagnosis and treatment of hemorrhoids (2020) , patients who are diagnosed with grade II-III internal hemorrhoids .\n2. Patients who voluntarily participate and sign the informed consent form.\n\nExclusion Criteria:\n\n1. patients who had severe heart, liver, and kidney disease.\n2. patients who had severe immune deficiency.\n3. patient\\'s general condition is too poor to tolerate endoscopic therapy.\n4. patients had a history of pelvic chemoradiotherapy.\n5. patients had severe infection or inflammatory lesion in the rectum or anal canal,or the rectum or anal canal had undergone surgery.\n6. patient is a pregnant woman.\n7. patients who disagree with endoscopic treatment and are concerned about the possible risks refused to sign the informed consent form.\n8. the follow-up time is insufficient and the clinical data were incomplete.","90 Years",{"count":556,"type":22},96,[87],"Endoscopic superior rectal mucosal ligation and hemorrhoids ligation are two types of endoscopic ligation, The aim of this study is to compare the clinical efficacy and safety of these two approaches.If you accept this study,you need to provide case information before the operation, complete the endoscopic treatment according to the routine colonoscopy procedure, and follow-up survey after the operation.",[560],"Hemorrhoids","2024-10-17",{"date":563,"type":40},"2024-10-21",{"date":565,"type":22},"2024-11-01",{"date":567,"type":22},"2026-04-30",{"name":46,"class":47},{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":576,"enrollmentInfo":577,"targetDuration":4,"studyType":23,"phases":579,"briefSummary":580,"conditions":581,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":48},"100559886","the-effects-of-colorectal-prehabilitation-via-reinfusion-or-retention-enema-of-ileal-contents-filtrate-on-the-defecation-functions-for-the-lar-patients-with-ileostomy-before-stoma-closure-100559886","NCT06569966","The Effects of Colorectal Prehabilitation Via Reinfusion or Retention Enema of Ileal Contents Filtrate on the Defecation Functions for the LAR Patients With Ileostomy Before Stoma Closure","The Effects of Colorectal Prehabilitation Via Reinfusion or Retention Enema of Ileal Contents Filtrate on the Defecation Functions for the LAR Patients With Ileostomy Before Stoma Closure: A Single Center Prospective Randomized Controlled Study","Inclusion Criteria:\n\n* aged 18-85 years old\n* Karnofsky performance status (KPS)≥70%; Or ECOG score 2 points or less\n* rectal cancer confirmed by preoperative pathology\n* in the rectum resection before low, low colorectal anastomosis or after neoadjuvant therapy of patients\n* prophylactic ileostomy.\n\nExclusion Criteria:\n\n* cannot complete treatment\n* the history of the anorectal surgery\n* preoperative bowel dysfunction such as diarrhea, irritable bowel syndrome and functional constipation, etc.)\n* postoperative anastomotic fistula and stricture\n* during pregnancy or breastfeeding women\n* with uncontrolled seizures, central nervous system disease or a history of mental disorders\n* the last five years have other history of malignant disease cured except skin cancer and cervical carcinoma in situ\n* clinically significant (i.e., active) heart disease, such as symptomatic coronary artery disease, New York Heart Association class II or worse 9) severe congestive heart failure or major arrhythmia requiring medical intervention, or myocardial infarction within the previous 6 months\n* has a history of cerebral infarction or cerebral hemorrhage within the past 6 months\n* organ transplantation requiring immunosuppressive therapy\n* serious uncontrolled repeated infections, or other serious with disease of control;\n* moderate or severe renal impairment creatinine clearance equal to or less than 50ml\u002Fmin, or upper limit of normal (ULN)\n* emergency surgery due to tumor emergencies (bleeding, perforation, obstruction)\n* in screening the first 4 weeks received study medication or treatment (to participate in other test).","85 Years",{"count":578,"type":22},154,[87],"This study was a single-center RCT study to compare the effect of preoperative prehabilitation treatment of ileostomy contents filtrate reinfusion through distal ileocolon or retention of enema colon with that of traditional treatment in patients with bowel function after stoma closure.",[582],"Low Anterior Resection Syndrome","2024-08-22",{"date":585,"type":40},"2024-08-26",{"date":587,"type":40},"2021-07-01",{"date":589,"type":22},"2024-12",{"name":46,"class":47},{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":4,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":598,"targetDuration":4,"studyType":23,"phases":599,"briefSummary":600,"conditions":601,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":616,"locationsCount":48},"100557946","phase-1-scg142-tcr-t-cells-for-human-papillomavirus-associated-carcinomas-100557946","NCT06544720","SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas","A Phase 1 Clinical Study of Autologous TCR-T Cells (SCG142) Therapy for Advanced HPV Associated Carcinomas","Key Inclusion Criteria:\n\n1. Greater than or equal to 18 years of age\n2. HPV associated carcinomas\n3. Patients must have at least one measurable lesion defined by RECIST 1.1\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n\nKey Exclusion Criteria:\n\n1. Active or uncontrollable infections or other active major medical illnesses of the cardiovascular, respiratory.\n2. Patients with active autoimmune diseases.\n3. Patient has a known active Hepatitis B or Hepatitis C.\n4. Other severe medical conditions that may limit subject\\'s participation in this trial.",{"count":21,"type":22},[25],"A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.",[602,603,604,605,606,607,608,609],"Human Papillomavirus Associated Carcinomas","Cervical Cancer","Head and Neck Cancers","Anal Cancer","Vulva Cancer","Vaginal Cancer","Penile Cancer","HPV-Related Malignancy","2024-08-06",{"date":612,"type":40},"2024-08-09",{"date":614,"type":40},"2023-08-02",{"date":300,"type":22},{"name":46,"class":47},""]